Results 101 to 110 of about 33,329 (197)

Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms

International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 1094-1102, October 2026.
ABSTRACT Introduction RUNX1 is a commonly mutated transcriptional regulator of hematopoiesis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mutated RUNX1 (mRUNX1) may associate with cross‐lineage immunophenotypic aberrancy, presenting potential complications for blast lineage assignment at diagnosis. Methods Clinical and laboratory
Yi Han Xia, Eric McGinnis
wiley   +1 more source

CD133 defines hair-inductive cells in the dermal papilla

Scientific Reports
A major contributing factor to the failure of cell-based human hair follicle (HF) engineering is our inability to cultivate highly specialized, inductive mesenchymal fibroblasts, which reside in a unique niche at the HF base, called the dermal papilla ...
Huangying Zhao, Linli Zhou, Lindsey G. Siegfried, Steven Boyce, Dorothy Supp, Thomas Andl, Yuhang Zhang   +6 more
doaj   +1 more source

CD133: to be or not to be, is this the real question?

American journal of translational research, 2014
CD133 (promini-1) is a member of the transmembrane glycoprotein family, was initially described as a specific marker to select human hematopoietic progenitor cells. Then, it was recognised as important marker to identify and isolate the specific cell subpopulation termed "cancer stem cells".
Elena, Irollo, Giuseppe, Pirozzi
openaire   +1 more source

Specific detection of CD133-positive tumor cells with iron oxide nanoparticles labeling using noninvasive molecular magnetic resonance imaging

International Journal of Nanomedicine, 2015
Ya-Wen Chen,1,2 Gunn-Guang Liou,3 Huay-Ben Pan,4,5 Hui-Hwa Tseng,5,6 Yu-Ting Hung,4 Chen-Pin Chou4,5,7,8 1National Institute of Cancer Research, National Health Research Institutes, Miaoli, 2Graduate Institute of Basic Medical Science, China Medical ...
Chen YW, Liou GG, Pan HB, Tseng HH, Hung YT, Chou CP   +5 more
doaj  

Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma. [PDF]

Gut
Pan Y, Zhang X, Wong CC, Chen H, Ma S, Lee TK, Yuan K, Liang C, Zhou X, Lau HCH, Huang P, Chen D, Wang L, Ding Y, Wei Q, Cheung AHK, To KF, Yu J.   +17 more
europepmc   +1 more source

Correction: Simbulan-Rosenthal et al. Employing CRISPR-Cas9 to Generate CD133 Synthetic Lethal Melanoma Stem Cells. <i>Int. J. Mol. Sci.</i> 2022, <i>23</i>, 2333. [PDF]

Int J Mol Sci
Simbulan-Rosenthal CM, Haribabu Y, Vakili S, Kuo LW, Clark H, Dougherty R, Alobaidi R, Carney B, Sykora P, Rosenthal DS.   +9 more
europepmc   +1 more source

Expression of EMT-Related Markers and CD133 in Non-Small Cell Lung Cancer: Associations with Clinicopathological Features and Prognosis. [PDF]

Cancer Manag Res
Wang Z, Bao M, Mei Y, Wu L.
europepmc   +1 more source

The Odf2 status contributes to asymmetric inheritance of CD133-positive recycling endosomes during cytokinesis in SK-N-DZ human neuroblastoma cells. [PDF]

iScience
Izumi H, Mae T, Tsukita S, Nakagawara A.
europepmc   +1 more source

Immunoexpression of stem cell markers CD44, CD133, ALDH1-2, and LGR5 in colorectal carcinoma and their association with clinicopathological tumor characteristics. [PDF]

Einstein (Sao Paulo)
Turke KC, Santos CD, Pagliari C, Testa GMG, Theodoro TR, Bianco B, Waisberg J.   +6 more
europepmc   +1 more source

Cancer Stem Cells in Colorectal Cancer: From Molecular Mechanisms to Diagnosis, Prognosis and Therapy Implications. [PDF]

Cancers (Basel)
Aiyejuto D, Luthria A, Hui T, Shenoy AK.
europepmc   +1 more source